Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
UroGen Pharma Ltd. | Chief Executive Officer | Ordinary Shares | 327K | $5.88M | $18.01 | Jan 31, 2023 | Direct |
Allogene Therapeutics, Inc. | Director | Stock Option (Right to buy) | 191K | Jun 5, 2024 | Direct | ||
UroGen Pharma Ltd. | Chief Executive Officer | Employee Stock Option (right to buy) | 125K | Jan 31, 2023 | Direct | ||
UroGen Pharma Ltd. | Chief Executive Officer | Performance Stock Units | 100K | Jan 31, 2023 | Direct | ||
UroGen Pharma Ltd. | Chief Executive Officer | Restricted Stock Units | 87.6K | Jan 31, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ALLO | Allogene Therapeutics, Inc. | Jun 5, 2024 | 1 | $0 | 4 | Jun 7, 2024 | Director |
URGN | UroGen Pharma Ltd. | Jan 31, 2024 | 1 | $0 | 4 | Feb 2, 2024 | Chief Executive Officer |
ALLO | Allogene Therapeutics, Inc. | Jun 13, 2023 | 1 | $0 | 4 | Jun 15, 2023 | Director |
URGN | UroGen Pharma Ltd. | Jan 31, 2023 | 7 | $0 | 4 | Feb 2, 2023 | Chief Executive Officer |
ALLO | Allogene Therapeutics, Inc. | Jun 15, 2022 | 1 | $0 | 4 | Jun 17, 2022 | Director |
URGN | UroGen Pharma Ltd. | Jan 31, 2022 | 7 | -$62.1K | 4 | Feb 2, 2022 | Chief Executive Officer |
URGN | UroGen Pharma Ltd. | Jan 3, 2022 | 3 | -$430K | 4 | Jan 7, 2022 | Chief Executive Officer |
ALLO | Allogene Therapeutics, Inc. | Jul 30, 2021 | 1 | $0 | 4 | Aug 3, 2021 | Director |
ALLO | Allogene Therapeutics, Inc. | Jul 30, 2021 | 0 | $0 | 3 | Aug 3, 2021 | Director |
URGN | UroGen Pharma Ltd. | Jan 3, 2021 | 6 | -$60K | 4 | May 21, 2021 | Chief Executive Officer |
URGN | UroGen Pharma Ltd. | Jun 3, 2020 | 14 | $0 | 4/A | Jul 12, 2021 | Chief Executive Officer |
URGN | UroGen Pharma Ltd. | Feb 3, 2020 | 8 | $0 | 4/A | Jul 12, 2021 | Chief Executive Officer |